A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge

Scientific Reports
Yu-Li LinBor-Luen Chiang

Abstract

Enterovirus 71 (EV71) is an aetiological agent responsible for seasonal epidemics of hand-foot-and-mouth disease, which causes considerable mortality among young children. Mucosal vaccines can efficiently induce secretory IgA at mucosal surfaces and thereby prevent or limit infection at the site of virus entry. CpG oligodeoxynucleotides (ODNs), which resemble bacterial DNA, can induce the innate immune response through activation of Toll-like receptor 9. Here, we used CpG ODNs as adjuvants to investigate an EV71 mucosal vaccine in mice. In the EV71 + CpG group, the EV71-specific IgG and IgA titres in the serum, nasal wash, bronchoalveolar lavage fluid, and faeces were substantially higher than those in the EV71- and phosphate-buffered saline-treated groups. Moreover, the number of EV71-specific IgG- and IgA-producing cells was also higher in the EV71 + CpG group. Furthermore, T-cell proliferative responses and interleukin-17 secretion were markedly increased when CpG-adjuvanted EV71 was delivered intranasally. More importantly, the induced antibodies neutralised infection by EV71 of the C2 genotype and crossneutralised infection by EV71 of the B4 and B5 genotypes. Lastly, human scavenger receptor class B, member 2-transgenic mi...Continue Reading

References

Dec 1, 1995·Virus Research·B A Brown, M A Pallansch
Jan 31, 2002·Immunologic Research·B S McKenzieA M Lew
May 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Prosper N BoyakaJerry R McGhee
Feb 19, 2004·European Journal of Immunology·Jörg VollmerArthur M Krieg
Apr 2, 2004·Nature Reviews. Immunology·Dennis M Klinman
Feb 24, 2006·Nature Reviews. Immunology·Marian R Neutra, Pamela A Kozlowski
Nov 10, 2009·Immunology Letters·Richard BrunnerIsabella Pali-Schöll
Nov 20, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Igor M Belyakov, Jeffrey D Ahlers
Oct 22, 2010·The Lancet Infectious Diseases·Tom SolomonMong How Ooi
Mar 10, 2015·Human Vaccines & Immunotherapeutics·Sumiko IhoFumiko Suzuki
Apr 12, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hao GuoLiguo Zhang
Jun 4, 2015·Emerging Microbes & Infections·Seiya YamayoshiSatoshi Koike
May 22, 2016·Expert Review of Vaccines·Yang ZhouFeng-Cai Zhu
Sep 13, 2016·International Journal of Environmental Research and Public Health·Ping-Chin ChangKow-Tong Chen
Nov 9, 2016·Korean journal of pediatrics·Kyung Yeon Lee
Feb 9, 2017·Clinical and Experimental Vaccine Research·Eun-Je YiSun-Young Chang
Jun 21, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Prosper N Boyaka
Jun 28, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Munir AkkayaSusan K Pierce

❮ Previous
Next ❯

Datasets Mentioned

BETA
AF304457.1

Methods Mentioned

BETA
enzyme-linked immunosorbent assays
bronchoalveolar lavage
bronchoalveolar
ELISA

Software Mentioned

ImmunoSpot

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.